Today, 85 per cent of children with leukaemia can be cured, but the outlook for patients over 60 is bleak. Only 10 per cent survive beyond one year as their cancer adapts to weather the storm of standard chemotherapy treatments. Associate Professor Steven Lane wants to change that outlook.
Steven and his team at the QIMR Berghofer Medical Research Institute have developed a method to rapidly profile the genetics of different leukaemia types—of which there are hundreds—and model them in the lab.
Cancer is the leading cause of death among people with HIV and yet cancer treatment can be risky as their immune system is already compromised.
Now, a new class of drugs developed at the Kirby Institute at the University of New South Wales is providing hope—demonstrating it is effective in treating the cancer and strengthening the immune response to that cancer.
By 2020, multiple sites worldwide will be trialing a non-invasive test for post-traumatic stress disorder (PTSD). The machine can determine if soldiers and emergency workers are prone to the disorder, and if so, they may be rested and not immediately deployed again.
Switching off T cells before they begin to damage the nervous system is the basis of an Australian therapy for multiple sclerosis (MS), which is expected to begin clinical trials by the end of 2017.
Developed by researchers at Victoria University in western Melbourne and the University of Patras in Greece, it brings together peptides, or protein fragments, with a biochemical delivery system already shown to be effective in cancer vaccine clinical trials. Continue reading Turning off toxic T cells in MS clinical trial→
The chances of surviving melanoma are getting better every year. But some cancers still become ‘resistant’ to treatment, and others don’t respond at all.
A collection of over 10,000 blood and 4,900 tissue samples from the biobank at the Melanoma Institute Australia is being used to hunt for clues to predict which patients won’t be responsive to treatment from day one. The researchers, from Macquarie University, are also looking for the basis of developed resistance by the cancer.
Pairing psychology with cancer treatment has a profound impact on the wellbeing of patients, Associate Professor Maria Kangas and her team at the Centre for Emotional Health have found.
In a recent clinical trial, head and neck cancer patients were offered weekly cognitive behavioural therapy (CBT) sessions concurrent to their radiation therapy appointments.
After just seven sessions, patients reported a significant decline in cancer-related anxiety and/or depression. And after a year, 67 per cent were no longer experiencing any anxiety or depression and were doing better than the control group who had received regular counselling, but not CBT.